Rutgers University said this week that Stephen Burley will be director of the Rutgers Center for Integrative Proteomics Research. He will assume the role in January, taking over for interim director Helen Berman.
Burley will be the first official director of the new 75,000 square-foot facility at Rutgers, which is part of a partnership with the University of Medicine and Dentistry of New Jersey.
Burley spent a decade at Rockefeller University, where he was a tenured professor and a Howard Hughes Medical Institute investigator. He also co-founded the drug discovery company Prospect Genomics and he was chief scientific officer at SGX Pharmaceuticals after it acquired Prospect in 2001. He was a distinguished researcher at Eli Lilly following its purchase of SGX four years ago.
Waters has named Indiana University's Laboratory of Biological Mass Spectrometry a Waters Center of Innovation and cited Professor David Clemmer for his contributions to ion mobility mass spectrometry and proteomics.
Clemmer is the Robert and Majorie Mann chair of chemistry and associate dean of sciences in the College of Arts and Sciences
Pressure Biosciences' stockholders have reelected Jeffrey Peterson and Wayne Fritzsche to continue serving on the firm's board of directors, the company said in a recent filing with the US Securities and Exchange Commission.
Peterson, who is chairman of the board, also is CEO of diagnostics company Target Discovery. Fritzsche, the founder of life sciences consulting firm Fritzshe & Associates, previously was PBI's board chairman from 2004 to 2012, and he serves on its scientific advisory board.